Document 5bk6Z65EJXvy8gb4wa529EjrJ

3M Specialty Materials Igfff December 20, 2001 3M Center St. Paul, MN 55144-1000 651 733 1110 A R Z G - lO If- fVj-Oi0l-Ol*72 iXti VED f* .f>; ' T p rJ : c Document Processing Center (7407) Office of Pollution Prevention and Toxics U.S. Environmental Protection Agency 401 M Street SW Washington, D.C. 20460 2202 J/iEi ~ 7 AilII: 0 3 Attention: For Your Information Docket - Docket No. AR-226 Re: Information on Perfluorooctane Sulfonates and Related Compounds Dear Sir or Madam: crsa rC-To3 U- This continues 3M's voluntary submissions of data on perfluorooctane sulfonates and CD related compounds, as part of our ongoing dialogue with EPA regarding fluorochemicate We are enclosing two studies as more fully described below. 9? Enclosed you will find the following: -CJO o -oUmo ;->0 1. Final Report, A Cross-sectional Analysis of Serum Perfluorooctanesulfonate (PFOS) and Perfluorooctanoate (PFOA) in Relation to Clinical Chemistry, Thyroid Hormone, Hematology and Urinalysis Results from Male and Female Employee Participants of the 2000 Antwerp and Decatur Fluorochemical Medical Surveillance Program, October 11, 2001. 2. Final Report, A Longitudinal Analysis of Serum Perfluorooctanesulfonate (PFOS) and Perfluorooctanoate (PFOA) Levels in Relation to Lipid and Hepatic Clinical Chemistry Test Results from Male Employee Participants of the 1994/95, 1997 and 2000 Fluorochemical Medical Surveillance Program, October 11, 2001. We will continue to provide information on a regular basis as it becomes available. We look forward to our continuing dialogue with the agency. Please feel free to contact me with any questions. FYI-00-001378 Very truly yours, i Michael A. Santoro Pi- A J. , ^ Director of Environmental, Health Safety and Regulatory Affairs Specialty Materials Markets 3M Building 236-IB-10 St. Paul, MN 55144 F Y I-00-001378 O U lblH A L 000Od0 / CONTAIN NO CB! 85020000008 85020000008